MARKET

IOVA

IOVA

Iovance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.18
+0.58
+1.43%
Opening 12:33 02/24 EST
OPEN
40.61
PREV CLOSE
40.60
HIGH
41.71
LOW
38.53
VOLUME
585.01K
TURNOVER
--
52 WEEK HIGH
54.21
52 WEEK LOW
18.70
MARKET CAP
6.04B
P/E (TTM)
-21.3800
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.
Benzinga · 4d ago
Global T-Cell Therapies Market Report 2021: Type of Therapy, Target Indications, Target Antigens, Key Players and Key Regions 2020-2030
Dublin, Feb 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 19, 2021 (GLOBE NEWSWIRE) -- The "Global T-Cell Therapies Market - Distribution by Type of...
GlobeNewswire · 5d ago
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results...
GlobeNewswire · 6d ago
The T-cell immunotherapy market is projected to grow at an annualized rate of 12.2%, claims Roots Analysis
London, Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- London, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of "Global T-Cell...
GlobeNewswire · 02/11 17:03
8-K: IOVANCE BIOTHERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- 0001425205 false 0001425205 2021-02-08 2021-02-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/09 18:46
BRIEF-Iovance Biotherapeutics Enters Into An Open Market Sale Agreement Of Up To $350.0 Million Of Shares
reuters.com · 02/09 11:21
Global T-Cell Therapy Market by Type of Therapy, Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2020-2030
New York, Feb 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 02/05 12:29
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:
GlobeNewswire · 01/19 13:56
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IOVA. Analyze the recent business situations of Iovance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IOVA stock price target is 51.45 with a high estimate of 60.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 415
Institutional Holdings: 164.06M
% Owned: 111.84%
Shares Outstanding: 146.69M
TypeInstitutionsShares
Increased
80
19.92M
New
93
-120.88K
Decreased
93
11.14M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
Chairman/Director
Iain Dukes
President/Chief Executive Officer/Director
Maria Fardis
Chief Financial Officer
Bellemin Shall
Chief Accounting Officer
Michael Swartzburg
General Counsel/Secretary
Frederick Vogt
Other
Friedrich Graf Finckenstein
Director
Athena Countouriotis
Independent Director
Ryan Maynard
Independent Director
Merrill McPeak
Independent Director
Wayne Rothbaum
Independent Director
Michael Weiser
  • Dividends
  • Splits
  • Insider Activity
No Data
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, it is investigating TIL therapy and peripheral blood lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer and chronic lymphocytic leukemia.

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.